MedTrace Logo

Methylphenidate to Improve Balance and Walking in MS

NCT01896700 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-04-05

Study results available
· View outcomes & findings →

Summary

Methylphenidate is an amphetamine-like psychomotor stimulant drug currently approved for the treatment of attention-deficit hyperactivity disorder (ADHD), postural orthostasis tachycardia syndrome and narcolepsy. It is also often prescribed off label to people with MS to improve fatigue. It is proposed that methylphenidate may also improve imbalance and walking deficits in MS by improving concentration and central integration, one of the primary mechanisms thought to underlie imbalance and walking deficits in MS.

Conditions

Interventions

DRUG

Methylphenidate

Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each

DRUG

Placebo

Escalating matched dose of placebo

Sponsors & Collaborators

  • Portland VA Medical Center

    collaborator FED

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Michelle Cameron, PT, MD · Portland VA Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01896700 on ClinicalTrials.gov